| Clinically isolated syndrome
Rebif vs Zeposia
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Rebif vs Zeposia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZeposia has a higher rate of injection site reactions vs Rebif based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zeposia but not Rebif, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rebif
Zeposia
At A Glance
SC injection
Three times per week
Interferon beta-1a
Oral
Once daily
S1P receptor modulator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
Dosing
Clinically isolated syndrome, Multiple Sclerosis Relapsing-Remitting, Multiple Sclerosis Secondary Progressive 22 mcg or 44 mcg SC three times per week; titrate starting at 20% of prescribed dose over a 4-week period to the targeted dose; administer at the same time on the same three days at least 48 hours apart each week.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Contraindications
- History of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
Adverse Reactions
Most common Injection site reaction, influenza-like symptoms, headache, fatigue, fever, leukopenia, elevated liver enzymes (SGPT, SGOT), myalgia, back pain, abdominal pain, depression
Serious Depression and suicide, hepatic injury, anaphylaxis and other allergic reactions, injection site necrosis, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, seizures
Postmarketing Drug-induced lupus erythematosus, autoimmune hepatitis, retinal vascular disorders, pulmonary arterial hypertension, erythema multiforme, Stevens-Johnson syndrome, hemolytic anemia
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Pharmacology
Interferon beta-1a; the exact mechanism(s) by which REBIF exerts its therapeutic effects in multiple sclerosis is unknown, but it is a recombinant form of human interferon beta produced in Chinese Hamster Ovary cells with an amino acid sequence identical to natural fibroblast-derived human interferon beta.
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rebif
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Rebif
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Rebif
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Zeposia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZeposiaView full Zeposia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.